First Line Management Development

  Getting your first line management role can be quite a challenge. Most first line managers will have spent several years being developed for...

Cultural Intelligence

HAVE YOU EVER WONDERED why we select candidates for Medical Representative positions largely on their personality and potential ability to develop relationships with customers...

Better Brains!

Most people in life never actively and deliberately use their brains. Sounds a strange statement to make but...

Compliance? Who Cares…..?

Are regulations negotiable?Who are the MHRA? Currently these are issues for all of us working in the pharma and...

New GP GMS contract – How to help practices increase quality and income

Paul Midgley of the Healthcare Partnership looks at the new GP GMS contract and examines how a ‘yes’ vote will help medical representativeswork more...

Tenders and Proposals

Preparing proposals is enough to make most people cringe. They take far too long to prepare, they’re absolutely boring...

Presenting With Magic

  In part three of our series on Presentation Skills we will be looking at ways to communicate and...

PCTs – Mission impossible for 2003?

SO WHAT IS IT that will be keeping PCTs, their Chief Executive’s and other members of the team awake at nights? This table gives...

Breathing in, and Breathing out: Pulmonary Drug Delivery Technologies

Although Millions of people depend on injectable medications for treatment of various ailments, none of them enjoy this experience. The pain, trauma and anguish...

The Strategy of Change

     I have chosen this subject because I would be very surprised if you have not already had considerable...

Latest articles

focus on science and not geography

Greater global collaboration: Time to focus on science and not geography

The Pistoia Alliance is urging industry stakeholders worldwide to focus on science and not geography, in a call for greater global collaboration. More than 250...
Accelerating the MedTech landscape

Accelerating the MedTech landscape

The Academic Health Science Networks (AHSN) in partnership with the Association of British HealthTech Industries (ABHI) has launched a report on accelerating the MedTech...
Tescaro present data from the GARNET study on dostarlimab in endometrial cancer. 

Tescaro present data on dostarlimab in endometrial cancer

Tescaro release positive results from the GARNET study on dostarlimab in endometrial cancer.  TESARO, an oncology-focused business acquired by GlaxoSmithKline plc, presents data from the...

Popular articles

Bristol-Myers Squibb-Pfizer Alliance announces results from Phase 4 AUGUSTUS trial.

AUGUSTUS trial demonstrates favourable safety results

The Bristol-Myers Squibb-Pfizer Alliance has announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis ® (apixaban) versus vitamin K antagonists (VKAs) in patients...
Smart phone image: Digital partnerships in pharma

Digital partnerships in pharma and the NHS

Can pharma and the NHS equal the fast pace of change necessary to fully embrace technological innovation? Over the last few years, slowly but surely,...
Trial results of Brilinta for heart attack patients following thrombolysis shows it met safety endpoint in secondary analysis of Phase III TREAT trial

Analysis of trial results of Brilinta for heart attack patients following thrombolysis

Analysis of trial results of Brilinta for heart attack patients following thrombolysis shows it met safety endpoint in secondary analysis of Phase III TREAT trial. The secondary...
The future of genomics

The future of genomics and precision medicine

How is the use of genomics data enhancing our medical understanding and what does this mean for the future of precision medicine? Genomics is one of...
Lixiana for Atrial Fibrillation

Daiichi Sanko announce results of two studies in the Edoxaban Clinical Research Programme

Daiichi Sankyo Company, Limited announces results from ELIMINATE-AF, a prospective, randomised, open label, blinded endpoint evaluation (PROBE) design study assessing the safety and efficacy...